Literature DB >> 2081514

Urinary calculi in hypercalcemic states.

W C Thomas1.   

Abstract

In this brief review of various hypercalcemic disorders and the likelihood of renal calculus formation, it is clearly evident that renal calculi occur much more often in hyperparathyroidism than in the other hypercalcemic states. Dystrophic calcification and nephrocalcinosis are common to all of the hypercalcemic disorders, including hyperparathyroidism, when the hypercalcemia is marked and the limit of solubility of calcium and phosphate in serum is approached. Interestingly, in sarcoidosis there are calcium oxalate crystals in variously distributed sarcoid granuloma, and the renal calculi are composed of calcium oxalate. By contrast, in hyperparathyroidism, the calculi composed of calcium phosphate predominate. This indicates a subtle and as yet undefined alteration in oxalate metabolism in sarcoidosis. An increase in urine pH occurs in hyperparathyroidism, and this enhances formation of crystalline calcium phosphate. However, the striking disparity between the frequency of calculus formation in hyperparathyroidism and that in other hypercalcemic disorders, several of which may be of relatively long duration, suggests that there indeed may be increased promoters of crystal formation in the urine of hyperparathyroid patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081514

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

1.  Hypercalcemic States associated with nephrolithiasis.

Authors:  Brandon L Craven; Corey Passman; Dean G Assimos
Journal:  Rev Urol       Date:  2008

2.  Precise determination of the absorptive component of urinary calcium excretion using stable isotopes.

Authors:  T R Welch; S A Abrams; L Shoemaker; A L Yergey; N Vieira; J E Stuff
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

Review 3.  Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?

Authors:  Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.